Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interferon alfa-2b
- Development stage
- Phase 4
- Lead developer
- Merck
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Intramuscular, Subcutaneous, Intralesional
01
Overview
Interferon alfa-2b is a recombinant form of human type I interferon produced using recombinant DNA technology. It is classified as an immunomodulator and cytokine with antiviral, antitumor, antiparasitic, and immunomodulatory activities. Interferon alfa-2b exerts its effects primarily by binding to the interferon alpha/beta receptor (IFNAR), activating the JAK-STAT signaling pathway. This leads to increased expression of genes involved in antiviral defense and immune modulation. The drug is used for the treatment of chronic hepatitis B and C infections, hairy cell leukemia, follicular lymphoma, malignant melanoma (especially after surgical removal), AIDS-related Kaposi's sarcoma, and genital warts. It may be used alone or in combination with other agents such as ribavirin for hepatitis C. Merck developed and manufactures this drug.
- Brand names
- Intron A
- Other names
- IFN-α2binterferon alpha 2brecombinant human interferon alpha 2b
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on interferon alfa-2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interferon alfa-2b.